Cargando…
The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
In 77 percent of patients suffering from a malignant carcinoid syndrome, administration of the somatostatin analog, octreotide (SMS 201-995, Sandostatin) induced clinical improvement coupled with a decrease in 24-hour urinary 5-hydroxyindole acetic acid (5-HIAA). This finding prompted an evaluation...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Yale Journal of Biology and Medicine
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2589749/ https://www.ncbi.nlm.nih.gov/pubmed/1364090 |